{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:34:16Z","timestamp":1791254056662,"version":"4.1.0"},"reference-count":42,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2007,8,14]],"date-time":"2007-08-14T00:00:00Z","timestamp":1187049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Experimental Allergy"],"published-print":{"date-parts":[[2007,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background\n\t\t\t\t\t<\/jats:bold> Lipoxin (LX) A<jats:sub>4<\/jats:sub>, an endogenous anti\u2010inflammatory eicosanoid, has been found to be low in patients with severe asthma. However, few studies also suggested more diminished LX A<jats:sub>4<\/jats:sub> levels in aspirin\u2010exacerbated respiratory disease (AERD) when compared with aspirin\u2010tolerant asthma (ATA). It is, therefore, currently not clear whether the asthma severity or the presence of AERD has a primary role in the disturbed LX metabolism.<\/jats:p><jats:p><jats:bold>Objective\n\t\t\t\t\t<\/jats:bold> To detect LX A<jats:sub>4<\/jats:sub> and 15\u2010epi\u2010LX A<jats:sub>4<\/jats:sub> levels in asthma patients with and without AERD of comparable severity.<\/jats:p><jats:p><jats:bold>Methods\n\t\t\t\t\t<\/jats:bold> The study groups consisted of 22 subjects with AERD, 22 subjects with ATA and 10 volunteers without asthma and aspirin sensitivity. Whole\u2010blood samples were stimulated with calcium ionophore, A23187 (5 \u00d7 10<jats:sup>\u22125<\/jats:sup>\u2003<jats:sc>m<\/jats:sc>) and A23187 (5 \u00d7 10<jats:sup>\u22125<\/jats:sup>\u2003<jats:sc>m<\/jats:sc>)+aspirin (10<jats:sup>\u22124<\/jats:sup>\u2003<jats:sc>m<\/jats:sc>). LX A<jats:sub>4<\/jats:sub> and 15\u2010epi\u2010LX A<jats:sub>4<\/jats:sub> levels were analysed by the enzyme immune assay method.<\/jats:p><jats:p><jats:bold>Results\n\t\t\t\t\t<\/jats:bold> Severe asthma patients in both AERD [0.5 (0.8)]\u2003ng\/mL and ATA [0.5 (0.45)\u2003ng\/mL] groups showed diminished generation for LX A<jats:sub>4<\/jats:sub> to stimulation with A23187 in comparison with other severity degrees in their groups (<jats:italic>P<\/jats:italic>=0.02 and 0.046, respectively). LX A<jats:sub>4<\/jats:sub> generation in both severe groups was comparable with each other (<jats:italic>P<\/jats:italic>&gt;0.05). Although severe cases with AERD showed a diminished capacity to generate 15\u2010epi\u2010LX A<jats:sub>4<\/jats:sub>, this did not reach statistical significance.<\/jats:p><jats:p><jats:bold>Conclusion\n\t\t\t\t\t<\/jats:bold> This study indicated that diminished LX A<jats:sub>4<\/jats:sub> generation was unique to severe asthma phenotype regardless of comorbid aspirin sensitivity.<\/jats:p><jats:p><jats:bold>Clinical Implications\n\t\t\t\t\t<\/jats:bold> Lower LX A<jats:sub>4<\/jats:sub> levels in severe asthma would suggest a possibility for LX analogues as future treatment options in these patients.<\/jats:p>","DOI":"10.1111\/j.1365-2222.2007.02806.x","type":"journal-article","created":{"date-parts":[[2007,8,16]],"date-time":"2007-08-16T22:27:24Z","timestamp":1187303244000},"page":"1494-1501","source":"Crossref","is-referenced-by-count":50,"title":["Lipoxin A<sub>4<\/sub> levels in asthma: relation with disease severity and aspirin sensitivity"],"prefix":"10.1111","volume":"37","author":[{"given":"G. E.","family":"\u00c7elik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. O.","family":"Erkekol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"M\u03b9s\u03b9rl\u03b9gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Melli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,8,14]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.07.024"},{"key":"e_1_2_6_3_2","first-page":"147","article-title":"Aspirin\u2010sensitive rhinosinusitis and asthma","volume":"19","author":"Kowalski ML.","year":"2007","journal-title":"Clin Allergy Immunol"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2222.2001.01074.x"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2005.12.053"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00063198-200401000-00009"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2222.2001.01074.x"},{"key":"e_1_2_6_8_2","first-page":"277","article-title":"Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria)","volume":"113","author":"Higashi N","year":"2004","journal-title":"involvement of chronic hyperplastic rhinosinusitis with nasal polyposis"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2222.2000.00953.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2222.2000.00953.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1159\/000082586"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2222.1999.00655.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2003.1491"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2005.00836.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2005.00836.x"},{"key":"e_1_2_6_16_2","first-page":"433","article-title":"Lipoxins and aspirin\u2010triggered 15\u2010epi\u2010lipoxin biosynthesis","volume":"68","author":"Serhan CN.","year":"2002","journal-title":"an update and role in anti-inflammation and pro-resolution"},{"key":"e_1_2_6_17_2","first-page":"81","article-title":"Lipid mediators","volume":"5","author":"Romano M.","year":"2006","journal-title":"lipoxin and aspirin-triggered 15-epi-lipoxins"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.plefa.2005.05.010"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.plefa.2005.05.002"},{"key":"e_1_2_6_20_2","first-page":"1145","article-title":"Lipoxins","volume":"65","author":"Kieran NE","year":"2004","journal-title":"potential anti-inflammatory, proresolution, and antifibrotic mediators in renal disease"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/154411130301400102"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3003.2000.16a08.x"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(03)01716-0"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200201-053OC"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.06.012"},{"key":"e_1_2_6_26_2","unstructured":"Global initiative for asthma. Global strategy for asthma management and prevention. National Institutes of Health publication. No: 02\u20103659 issued January 1995 (updated 2003)."},{"key":"e_1_2_6_27_2","first-page":"2341","article-title":"Proceedings of the ATS workshop on refractory asthma","volume":"162","author":"Fahy JV","year":"2000","journal-title":"current understanding, recommendations, and unanswered questions"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.09.038"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200410-1413OC"},{"key":"e_1_2_6_30_2","first-page":"804","article-title":"Asthma","volume":"368","author":"Wenzel S.","year":"2006","journal-title":"defining of the persistent adult types"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69288-X"},{"key":"e_1_2_6_32_2","first-page":"487","article-title":"Severe asthma","volume":"117","author":"Moore WC","year":"2006","journal-title":"an overview"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.01.039"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.08.009"},{"key":"e_1_2_6_35_2","first-page":"1027","article-title":"Lipoxins in asthma","volume":"59","author":"Bonnans C","year":"2004","journal-title":"potential therapeutic mediators on bronchial inflammation?"},{"key":"e_1_2_6_36_2","first-page":"373","article-title":"Exploring new approaches to the treatment of asthma","volume":"39","author":"Levy BD","year":"2003","journal-title":"potential roles for lipoxins and aspirin-triggered lipid mediators"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0902-931"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm748"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)52976-8"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.1979"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.132.6.579"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.07.050"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1398-9995.2003.23792.x"}],"container-title":["Clinical &amp; Experimental Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2222.2007.02806.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2222.2007.02806.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T21:57:56Z","timestamp":1697234276000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2222.2007.02806.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,14]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["10.1111\/j.1365-2222.2007.02806.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2222.2007.02806.x","archive":["Portico"],"relation":{},"ISSN":["0954-7894","1365-2222"],"issn-type":[{"value":"0954-7894","type":"print"},{"value":"1365-2222","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,14]]}}}